FDA Probes Generic Firms’ Liability Insurance In Context Of Labeling Rule
Executive Summary
FDA’s questions to generic drug sponsors about whether they carry liability insurance and the state of liability claims against them have industry reps puzzled.
You may also be interested in...
Generic Labeling Rule Becomes Statistical Battle As Public Meeting Looms
Report sponsored by trial lawyers states that even if proposed reg change does drive up generic drug prices, it likely would have little effect on consumer purchasing habits.
FDA Proposes Unilateral Generic Drug Label Changes, Signaling End To Liability Shield
FDA proposed rule would allow ANDA holders to unilaterally make label changes prior to FDA’s approval; NDA and other ANDA holders would have 30 days to revise their labels once FDA approves the change.
Generic Firms Get Supreme Shield From Product Liability, But Court Hints At Reg Change
In Pliva v. Mensing, the high court said it was impossible for generic manufacturers to comply with both state tort laws and FDA regulations requiring them to have the same labels as those for brand name counterparts.